Sarepta Therapeutics Inc (SRPT) : Venbio Select Advisor reduced its stake in Sarepta Therapeutics Inc by 2.99% during the most recent quarter end. The investment management company now holds a total of 1,369,909 shares of Sarepta Therapeutics Inc which is valued at $53,590,840 after selling 42,281 shares in Sarepta Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Sarepta Therapeutics Inc makes up approximately 10.02% of Venbio Select Advisor’s portfolio.
Other Hedge Funds, Including , National Asset Management added SRPT to its portfolio by purchasing 3,910 company shares during the most recent quarter which is valued at $154,523. Sarepta Therapeutics Inc makes up approx 0.03% of National Asset Management’s portfolio.California State Teachers Retirement System boosted its stake in SRPT in the latest quarter, The investment management firm added 900 additional shares and now holds a total of 90,509 shares of Sarepta Therapeutics Inc which is valued at $3,862,019. Sarepta Therapeutics Inc makes up approx 0.01% of California State Teachers Retirement System’s portfolio.Hudson Bay Capital Management Lp boosted its stake in SRPT in the latest quarter, The investment management firm added 84,619 additional shares and now holds a total of 539,619 shares of Sarepta Therapeutics Inc which is valued at $23,025,543. Sarepta Therapeutics Inc makes up approx 2.19% of Hudson Bay Capital Management Lp’s portfolio.Emerald Acquisition Ltd. reduced its stake in SRPT by selling 2,653 shares or 10.2% in the most recent quarter. The Hedge Fund company now holds 23,351 shares of SRPT which is valued at $996,387.Tiaa Cref Investment Management reduced its stake in SRPT by selling 8,422 shares or 3.25% in the most recent quarter. The Hedge Fund company now holds 250,460 shares of SRPT which is valued at $9,732,876. Sarepta Therapeutics Inc makes up approx 0.01% of Tiaa Cref Investment Management’s portfolio.
Sarepta Therapeutics Inc opened for trading at $38.86 and hit $39.362 on the upside on Monday, eventually ending the session at $38.74, with a gain of 0.03% or 0.01 points. The heightened volatility saw the trading volume jump to 20,04,759 shares. Company has a market cap of $2,115 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.33 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $-1.28.During the same quarter in the previous year, the company posted $-1.11 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Shares were Reiterated by RBC Capital Mkts on Oct 28, 2016 to “Outperform” and Lowered the Price Target to $ 106 from a previous price target of $108 .Morgan Stanley Initiated Sarepta Therapeutics Inc on Oct 27, 2016 to “Equal-Weight”, Price Target of the shares are set at $53.Credit Suisse Initiated Sarepta Therapeutics Inc on Oct 18, 2016 to “Outperform”, Price Target of the shares are set at $68.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.